Session 1 – When Overall Survival Cannot Be a Primary Endpoint

Reflection on the challenge – Axel Glasmacher (CDDF, DE)

Pathway towards solutions – Industry view – Chitkala Kalidas (Bayer, USA)

Pathway towards solutions – Industry view – Elmar Schmitt (Merck Healthcare KGaA, DE)

Pathway towards solutions – Regulatory view – Filip Josephson (EMA, SWE)

Session 2 – Endpoints in Expedited Approval Pathways

Patient perspective – Hans Scheurer (MPE, NL)

Regulatory perspective – Vishal Bhatnagar (FDA, USA)

HTA perspective – Carole Longson (NICE, UK) 

Session 3 – PRO Endpoints – Review of Strategies

Patient perspective – Jayne Galinsky (MPE, UK)

Regulatory perspective – Vishal Bhatnagar (FDA, USA)

Industry perspective – Paul Kamudoni (Merck Healthcare KGaA, UK)

HTA perspective – Leeza Osipenko (London School of Economics, UK)

Academic perspective – Corneel Coens (EORTC, BE)